Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tryptamine Therapeutics ( (AU:TYP) ) just unveiled an update.
Tryptamine Therapeutics has enrolled a second patient in its groundbreaking clinical trial using TRP-8803 to treat Binge Eating Disorder (BED). The first patient is scheduled to be dosed on December 1, 2025, marking the first clinical administration of TRP-8803 in a BED population. The trial, conducted in collaboration with Swinburne University and supported by the Butterfly Foundation, aims to recruit 12 patients and is expected to provide top-line results by the first quarter of 2026. This initiative highlights the growing recognition of BED as a significant mental health issue and underscores the importance of developing new therapeutic approaches.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on developing proprietary formulations of psilocin for use in psychotherapy to treat diseases with unmet medical needs. Their lead program, TRP-8803, is an IV-infused psilocin formulation designed to improve the administration of psychedelic therapy by reducing the time to onset, controlling the depth and duration of the experience, and making the intervention commercially viable.
Average Trading Volume: 2,495,811
Technical Sentiment Signal: Buy
Current Market Cap: A$51.98M
See more insights into TYP stock on TipRanks’ Stock Analysis page.